Sendero Wealth Management LLC Buys 9,153 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Sendero Wealth Management LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 25.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 45,221 shares of the medical research company’s stock after acquiring an additional 9,153 shares during the period. IQVIA accounts for approximately 1.3% of Sendero Wealth Management LLC’s investment portfolio, making the stock its 15th biggest holding. Sendero Wealth Management LLC’s holdings in IQVIA were worth $8,886,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Laurel Wealth Advisors LLC grew its stake in IQVIA by 3.2% during the 4th quarter. Laurel Wealth Advisors LLC now owns 4,572 shares of the medical research company’s stock worth $898,000 after buying an additional 140 shares during the last quarter. Fifth Third Wealth Advisors LLC boosted its holdings in IQVIA by 26.1% in the fourth quarter. Fifth Third Wealth Advisors LLC now owns 1,839 shares of the medical research company’s stock worth $361,000 after acquiring an additional 381 shares in the last quarter. Community Trust & Investment Co. grew its stake in shares of IQVIA by 4.9% during the fourth quarter. Community Trust & Investment Co. now owns 77,240 shares of the medical research company’s stock worth $15,178,000 after acquiring an additional 3,634 shares during the last quarter. Cullen Investment Group LTD. increased its holdings in shares of IQVIA by 1.3% during the fourth quarter. Cullen Investment Group LTD. now owns 20,575 shares of the medical research company’s stock valued at $4,043,000 after acquiring an additional 267 shares in the last quarter. Finally, Pallas Capital Advisors LLC purchased a new position in shares of IQVIA in the 4th quarter valued at approximately $298,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of NYSE IQV opened at $196.01 on Thursday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The firm has a fifty day moving average of $201.43 and a 200 day moving average of $221.61. The firm has a market cap of $35.58 billion, a PE ratio of 25.72, a PEG ratio of 2.09 and a beta of 1.48. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on IQV shares. Bank of America cut their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. TD Cowen reduced their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Evercore ISI dropped their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $255.82.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.